N J Raymond1, T K Blackmore, M W Humble, M R Jones. 1. Department of Internal Medicine, Infectious Disease Serevice, Wellington Hospital, Wellington, New Zealand. nigel.raymond@ccdhb.org.nz
Abstract
BACKGROUND: Bloodstream infections (BSI) occurring in community and health-care settings vary with the patient group and treatment of underlying medical conditions. We studied the clinical infectious syndromes occurring in patients with positive blood cultures routinely obtained at a regional secondary and tertiary care hospital. METHODS: BSI were categorized as either community-acquired (C-BSI), or health-care-associated (H-BSI) acquired either as a (i) non-inpatient (outpatient) or (ii) hospital inpatient. Clinical information was collected prospectively during the 1-year study. RESULTS: There were 193 C-BSI and 230 H-BSI. The large majority of C-BSI were caused by bacterial pathogens susceptible to narrow-spectrum antibiotics, particularly in children. Cefuroxime was active against 90% of C-BSI isolates and 46% of H-BSI isolates, excluding anaerobes. Of all H-BSI, the 35% occurring in outpatients had a similar source, microbiological cause and bacterial susceptibilities to the inpatients. H-BSI were infrequently due to enterococci (4%), Candida (3%) or methicillin-resistant Staphylococcus aureus (0.4%). No BSI were due to vancomycin-resistant enterococci or extended-spectrum beta-lactamase producing Enterobacteriaciae. I.v. catheters, predominantly central lines, were the source of 60% of all H-BSI, mostly in haematology-oncology or neonatal patients. Mortality at 1 month was 12% overall for both C-BSI and H-BSI, varying markedly by underlying disease and increasing age (for C-BSI). CONCLUSION: In this population, C-BSI have remained susceptible to narrow-spectrum antibiotics, whereas H-BSI due to multiresistant organisms were rare. Obtaining a history of recent medical procedures is important for community patients presenting with a BSI.
BACKGROUND: Bloodstream infections (BSI) occurring in community and health-care settings vary with the patient group and treatment of underlying medical conditions. We studied the clinical infectious syndromes occurring in patients with positive blood cultures routinely obtained at a regional secondary and tertiary care hospital. METHODS: BSI were categorized as either community-acquired (C-BSI), or health-care-associated (H-BSI) acquired either as a (i) non-inpatient (outpatient) or (ii) hospital inpatient. Clinical information was collected prospectively during the 1-year study. RESULTS: There were 193 C-BSI and 230 H-BSI. The large majority of C-BSI were caused by bacterial pathogens susceptible to narrow-spectrum antibiotics, particularly in children. Cefuroxime was active against 90% of C-BSI isolates and 46% of H-BSI isolates, excluding anaerobes. Of all H-BSI, the 35% occurring in outpatients had a similar source, microbiological cause and bacterial susceptibilities to the inpatients. H-BSI were infrequently due to enterococci (4%), Candida (3%) or methicillin-resistant Staphylococcus aureus (0.4%). No BSI were due to vancomycin-resistant enterococci or extended-spectrum beta-lactamase producing Enterobacteriaciae. I.v. catheters, predominantly central lines, were the source of 60% of all H-BSI, mostly in haematology-oncology or neonatal patients. Mortality at 1 month was 12% overall for both C-BSI and H-BSI, varying markedly by underlying disease and increasing age (for C-BSI). CONCLUSION: In this population, C-BSI have remained susceptible to narrow-spectrum antibiotics, whereas H-BSI due to multiresistant organisms were rare. Obtaining a history of recent medical procedures is important for community patients presenting with a BSI.
Authors: Pilar Retamar; María Dolores López-Prieto; Clara Nátera; Marina de Cueto; Enrique Nuño; Marta Herrero; Fernando Fernández-Sánchez; Angel Muñoz; Francisco Téllez; Berta Becerril; Ana García-Tapia; Inmaculada Carazo; Raquel Moya; Juan E Corzo; Laura León; Leopoldo Muñoz; Jesús Rodríguez-Baño; Fernando Rodríguez-López; María V García; Verónica Fernández-Galán; Alfonso del Arco; María J Pérez-Santos; Antonio Sánchez Porto; Manuel Torres-Tortosa; Andrés Martín-Aspas; Ascensión Arroyo; Carolina García-Figueras; Federico Acosta; Carmen Florez; Petra Navas; Trinidad Escobar-Lara Journal: BMC Infect Dis Date: 2013-07-24 Impact factor: 3.090
Authors: M Lafaurie; E d'Anglejan; J L Donay; D Glotz; E Sarfati; M Mimoun; M Legrand; E Oksenhendler; M Bagot; S Valade; B Bercot; J M Molina Journal: BMC Infect Dis Date: 2020-02-14 Impact factor: 3.090
Authors: K L Henderson; B Müller-Pebody; A Wade; M Sharland; M Minaji; A P Johnson; R Gilbert Journal: Epidemiol Infect Date: 2014-12-08 Impact factor: 2.451